A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus

NCT07001839 | Not Yet Recruiting Phase 1

• 1 other identifier: QLS4131-201
• Study Type: interventional
• Target: 108
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this open label, dose escalation phase 1b clinical trial is to investigate the safety, tolerability, pharmacokinetic, pharmacodynamics, immunogenicity and preliminary clinical efficacy of QLS4131 in subjects with systemic lupus erythematosus (SLE). The main questions it aims to answer are:

• The safety, tolerability and maximum tolerated dose (MTD) of QLS4131 for Injection in participants with SLE.
• The recommended Phase 2 dose (RP2D) of QLS4131 for Injection in participants with SLE. Participants will be administered different target dose of QLS4131 for Injection only once. A step-up dosing approach will be implemented at high dose level as determined by the safety monitoring committee.

Conditions

Systemic Lupus Erythematosus

Keywords

QLS4131; Systemic lupus erythematosus; T cell engager

Outcome Measures

Primary Outcomes (2)

• incidence of treatment emergence adverse events.

  Up to 24 weeks]

• Recommended Phase 2 Dose

  Approximately 24 weeks

Study Arms (1)

QLS4131

EXPERIMENTAL

Target dose of each cohort will be administered only once

Drug: QLS4131 for Injection.

Interventions

QLS4131 for Injection. DRUG

Eligible participants will be assigned to 1 of the 9 dose groups ranging from 0.06 μg/kg to 600 μg/kg.

QLS4131

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18 to 70 (inclusive);
• Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (ACR) Classification Criteria at least 12 weeks or more prior to screening;
• Participants with positive antinuclear antibody (ANA) (≥ 1:80), or positive anti-dsDNA antibody and/or positive anti-Sm antibody at screening;
• Active SLE disease at screening, as demonstrated by a SLEDAI-2K \>= 8 at screening, or SLEDAI-2K \>= 6 at the presence of low complement and/or positive anti-dsDNA antibodies;
• Current receipt of one or more of the following classes of standard therapies for the treatment of SLE at stable doses: oral corticosteroids, antimalarial agents, and conventional immunosuppressants:
• For participants receiving an oral corticosteroid, treatment with ≤40 mg/day prednisone or equivalent, at a dose that has been stable for at least 4 weeks prior to first dose;
• For participants receiving an antimalarial, the medication(s) must have been at a stable dose ≥ 4 weeks prior to the first dose;
• For participants receiving immunosuppressants, treatment with a single immunosuppressant at a stable dose for ≥ 4 weeks prior to the first dose: conventional immunosuppressants include azathioprine, mycophenolate mofetil, mycophenolic acid, and methotrexate (oral, subcutaneous or intravenous routes).
• Participants who understand and abide by the study procedures, voluntarily participate in this study, and sign the Informed Consent Form in person.

You may not qualify if:

• Participants with known intolerance or allergy to the investigational product or drugs that may be used in the study (e.g., Tocilizumab) and any components;
• Participants with active severe active or unstable lupus-associated neuropsychiatric disease;
• Participants with other autoimmune diseases that may affect the efficacy evaluation;
• Participants with poorly controlled hypertension and diabetes;
• Participants with severe lupus nephritis;
• Participants with a history of malignancy within 5 years prior to screening;
• Participants with a previous history of vital organ transplantation;
• Participants who have had opportunistic infections within 12 weeks prior to the first dose;
• Receipt of any CAR-T, CAR-NK or other gene therapy;
• Pregnant or lactating women.

Sponsors & Collaborators

• Qilu Pharmaceutical Co., Ltd.: lead

MeSH Terms

Conditions

Lupus Erythematosus, Systemic

Interventions

Injections

Condition Hierarchy (Ancestors)

Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Drug Administration Routes; Drug Therapy; Therapeutics

Central Study Contacts

Dandan Guo, PM

CONTACT

13668889421; dandan1.guo@qilu-pharma.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 25, 2025
• First Posted: June 3, 2025
• Study Start: June 1, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: June 3, 2025

Record last verified: 2025-05